MOMO'S BREAKOUT BOARD

[2times2]

IDNG entry now: Debt elimination; sales of SANDD mini™ device; Famous DR. Drew as new consultant and promoter; subsidies with improved revenues; HAWK as new trading symbol soon; Float t.b. reduced by ~10%; Warrants (at half a cent) now held by Institutional Investor/Beechwood

OS 858M 07/29/2019; Unrestricted 650M

SEC Reporting/Audited Financials

News July 25 2019 8K: RedHawk Medical Products & Services LLC entered into a Consultant Agreement (“Agreement”) with Drew Pinsky, Inc. (“DPI”) f/s/o Dr. Drew Pinsky, for Consultant to be the exclusive spokesperson for the Company’s Sharps Needle and Destruction Device (“ SAN DD”) mini™, SAN DD Pro™ and any related products and/or accessories (“Products”) for an initial period of two years.
https://www.otcmarkets.com/filing/conv_pdf?id=13552470&guid=6X7IUpZDTYxu3th

News June 24 2019 8K: Debt eliminated: Holders of $574,250 aggregate principal amount of the Company’s 5% convertible promissory notes, including accrued interest, have converted their Notes into 114,849,929 shares of Common Stock
https://ih.advfn.com/stock-market/USOTC/independence-energy-corp-IDNG/stock-news/80192394/current-report-filing-8-k

News June 24 2019 8K: Warrants at half a cent: Beechwood now holds a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of Common Stock at an exercise price of $0.005 per share. The Warrant expires June 20, 2029.
https://ih.advfn.com/stock-market/USOTC/independence-energy-corp-IDNG/stock-news/80192394/current-report-filing-8-k

Revenues in the pharmaceutical and medical device business unit are expected to improve as market acceptance of our products increases and we begin sales of our SANDD medical devices. Additionally, net profits are expected to improve as the Company’s pharmaceutical sales become more weighted to its branded generics which offer lower discounts than the discounts offered by the Company for its highly competitive “special” pharmaceuticals and require significantly lower operating costs. Additionally, our medical devices are being offered for sale at very attractive profit margins.
https://www.otcmarkets.com/stock/IDNG/security

News June 17, 2019 RedHawk Holdings Corp. announced today that it has engaged Black Mountain Pharma Ltd. to assist RedHawk Medical Products and Services, LLC and RedHawk Medical Products UK Ltd (collectively referred to herein as "RedHawk Medical Products"), wholly-owned subsidiaries of the Company, in the transition and ongoing maintenance of its current FDA-approved quality management system to the higher and more stringent international medical device standard, ISO 13485:2016.
Black Mountain Pharma Ltd (www.blackmountainpharma.com) was established in 2012 to provide professional Regulatory Affairs ("RA") and Quality Assurance ("QA") support for developing, implementing and sustaining quality management systems and for establishing regulatory affairs strategies for businesses associated with medical devices, pharmaceuticals, cosmetics and foods.
Led by Dr. Christopher W. Smejkal, the Black Mountain global team of professionals has a long history of developing, implementing and sustaining management systems and establishing regulatory affairs strategies for businesses associated with medical devices and pharmaceuticals. Dr. Christopher Smejkal from Black Mountain Pharma Ltd has joined RedHawk as its RA/QA consultant. He will act as the Company's Responsible Person for distribution of branded generic pharmaceuticals in the UK. Dr. Smejkal holds Bachelor of Science and Doctor of Philosophy (PhD) degrees in Biological Sciences from the University of Exeter, United Kingdom and a Master of Business Administration degree from the Open University, United Kingdom. He has extensive experience working in both the medical device and pharmaceutical industries as a senior RA/QA Professional.
ISO 13485:2016 specifies global requirements for a quality management system where an organization must demonstrate its ability, and the ability of its suppliers, to provide medical devices and related services that consistently meet customer and applicable international regulatory requirements.
As RedHawk Medical Products' business focuses on the development and sales of the Sharps and Needle Disintegration Devices (SANDD™) line of products, ISO 13485:2016 will become an integral part of RedHawk Medical Products' business culture and the way in which it operates.
ISO 13485 was specifically developed with the objective of harmonizing medical device regulatory requirements for quality management systems in major markets around the world including the United States, Europe, Canada, Japan and Australia. ISO 13485 and meets, or exceeds, all U.S. Food and Drug Administration Quality System Regulations Standard 21 CFR 820 which was established in 1978 to outline Current Good Manufacturing Practices in the United States.

News June 13, 2019: REDHAWK HOLDINGS CORP. announced today the appointment of Philip C. Spizale to its board of directors ("Board") effective July 1, 2019. Mr. Spizale has more than 25 years of sales, marketing and management experience in the healthcare industry and has served as a healthcare advisor to the Board since November 2017. Mr. Spizale will assist the Company in developing its sales and marketing strategies for its line of SANDD™ needle incineration units.
In 2016, Mr. Spizale joined REVA, Inc., the largest fixed wing air medical transport service provider in the Americas, as its Chief Sales Officer. Prior to joining REVA, Inc., Mr. Spizale held various senior sales and managerial positions with Concentra Inc. between 2003 and 2016. Concentra Inc. is a national health care provider of a wide range of medical services to employers and patients, including urgent care, occupational medicine, physical therapy, primary care, and wellness programs.

We are currently accepting orders for our SANDD mini™ and within the next thirty (30) days, we plan to commence deliveries of the SANDD mini™ into the Texas school systems."

The Company also announced today that it has completed the acquisition of the following internet domains – hawc.com, sanddmini.com, sanddpro.com and instantreassurance.com.
https://ih.advfn.com/stock-market/USOTC/independence-energy-corp-IDNG/stock-news/80127945/healthcare-industry-veteran-appointed-to-redhawk-b

News May 10, 2019: RedHawk Expands Sandd Sales Infrastructure
https://www.otcmarkets.com/stock/IDNG/news/story?e&id=1354800
LAFAYETTE, LA / ACCESSWIRE /RedHawk Holdings Corp. (OTC PINK: IDNG) ("RedHawk" or the "Company") announced today that it has entered into a customer-specific sales representation agreement with Jeeds Health, Inc., an affiliate of Pharmaceutical Buyers, Inc. ( "PBI" - www.pharmaceuticalbuyersinc.com ), for the sale of its SANDD mini ("Sharps and Needle Destruction Device") needle destruction devices. The Company believes the agreement will eventually extend to the SANDD Pro unit when it is offered for sale later in 2019.

PBI, a New York-based company headquartered in Long Island, New York, sources and distributes clinical trial, biologic and specialty drugs to approximately 285 major pharmaceutical and biotech companies in the United States and overseas. Through an affiliate, R&H Pharmacy, PBI distributes prescription, medication, vitamins, supplements and over-the-counter items to various wholesalers in the European Union.

PBI serves an active base of about 285 major pharmaceutical related companies in the United States and in over 30 other countries in the branded, generic and biotech/pharmaceutical industry and include virtually all major generic drug manufacturers

Landmark update: Law suit, which caused the pps drop over a year, settled 3/25/2019 https://ih.advfn.com/stock-market/USOTC/independence-energy-corp-IDNG/stock-news/79546575/current-report-filing-8-k?_ga=2.246315271.2034152483.1553442777-818680873.1541627246 - also leading to return of 52M shares to the treasury

RedHawk Holdings Corp. 5/4/19 By Stockmarkerquarter - independent profiler on emerging growth companies:
https://stockmarketquarter.com/
RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD Needle Destruction Unit (formerly known as the Disintegrator), the Carotid Artery Digital Non-Contact Thermometer and Zonis. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner. http://www.redhawkenergycorp.com

The Company said its health care business unit will operate as a fully-owned subsidiary of RedHawk under the name Independence Health Corp., LLC.
The Company is waiting for regulatory approval to begin trading under its new trading symbol (HAWC) and new CUSIP number (75746Q103).


List of subsidiaries:
100% owned by IDNG/REDHAWK:

1.RedHawk Land and Hospitality

2.RedHawk Medical Products & Service
(www.needledestructiondevice.com

3.RedHawk Medical Products UK
(http://redhawkmedical.co.uk)

4.RedHawk Pharma, LLC

5.EcoGen Europe LTD
(https://ecogen-europe.co.uk)

6.RedHawk Pharma UK LTD

7.RedHawk Financial Services, LLC

8.RedHawk Energy Corp., LLC
(http://redhawkenergycorp.com)

9.Centri Security Systems, LLC